Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research
Advertisement
Johnson & Johnson announced that Axel Ullrich, Ph.D., director of the Department of molecular biology at the Max Planck Institute of biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin® (trastuzumab), is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists selected Dr. Ullrich, who on September 8 will receive a $100,000 prize during a ceremony in Beerse, Belgium.
"Dr. Ullrich was chosen for his pioneering work in applying molecular biology and molecular cloning to the discovery of protein therapeutics for the treatment of a wide range of diseases, including diabetes and cancer," said Solomon Snyder, M.D., distinguished service professor of Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of Medicine and chairman of The Dr. Paul Janssen Award Selection Committee.
Ullrich has pioneered the translation of genomics-based discoveries into novel approaches for the treatment of major diseases. Working at Genentech, Inc. in the early 1980s, he developed genetically engineered human insulin, the first therapeutic derived from gene cloning. In 1987, Ullrich and collaborators discovered that the neu/HER2 gene is amplified and overexpressed in more than 30 percent of invasive breast cancers. HER2 was chosen for the development of an entirely novel cancer therapy, culminating in the production of an anti-HER2 monoclonal antibody that since 1998 has been used successfully to treat patients with metastatic breast cancer. This was the first targeted therapeutic agent developed on the basis of a newly discovered gene with an oncogenic function in human cancer.
In the early 1990s, Ullrich identified the signaling system involved in regulating tumor angiogenesis, the growth of blood vessels in tumors. He discovered that inhibiting a key player in the signaling system (called vascular endothelial growth factor receptor or VEGFR) suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor of the VEGFR2 kinase function was developed, from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors.
"It is an honor to receive an award of this stature and to be recognized among so many outstanding scientists," said Ullrich. "Dr. Paul is a legend whose work had a tremendous impact on combating some of the world's most serious diseases. Four of the more than 80 medicines he developed are on the World Health Organization's list of essential medicines."
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Currently positioned only 5th, China is the fastest growing biotech market in the world
BGU researchers make scientific breakthrough in the fight against neurodegenerative diseases - BGN Technologies secures funding of over $1m. to develop patented treatment
Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment
Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression
Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years
MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial
Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer
New findings about stem cells in the brain of patients with epilepsy
